PMV Pharmaceuticals, Inc. (NasdaqGS: PMVP)
Health Care · Biotechnology · US
$1.39
-8.55% today · +15.2% 1Y
PMV Pharmaceuticals, Inc. (NasdaqGS: PMVP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $114.78M and employs 54 people.
Over the last twelve months the share price has gained 15.2%, trading between 1.02 and 1.91.
Tweenvest scores PMV Pharmaceuticals, Inc. across four factors: quality 38/100, value 57/100. Its strongest factor is value.
PMVP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $114.78M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.41
- Dividend yield
- —
- Beta (5Y)
- 1.35
- 52-week high
- $1.91
- 52-week low
- $1.02
- Avg volume (3M)
- —
- Shares outstanding
- 75.51M
- Employees
- 54
- Next earnings
- —
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
- ISIN
- US69353Y1038
- Founded
- 2013
- Listed since
- Sep 25, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Heidelberg Pharma AGXTRA: HPHA | $116.82M | €2.23 | -5.11% |
| Coya Therapeutics, Inc.NasdaqCM: COYA | $116.12M | $4.58 | -7.47% |
| enGene Therapeutics Inc.NasdaqCM: ENGN | $115.94M | $1.65 | -4.62% |
| 4basebio PLCAIM: 4BB | $115.66M | £5.63 | 0.00% |
| Genelux CorporationNasdaqCM: GNLX | $114.72M | $2.53 | -1.37% |
| Unicycive Therapeutics, Inc.NasdaqCM: UNCY | $114.49M | $3.86 | -6.08% |
| Inovio Pharmaceuticals, Inc.NasdaqCM: INO | $114.25M | $1.02 | -8.14% |
| Tonix Pharmaceuticals Holding Corp.NasdaqGS: TNXP | $113.88M | $6.52 | -1.81% |
Figures last refreshed Oct 11, 2026.